Premium
Contrast‐Enhanced Transvaginal Sonography of Benign Versus Malignant Ovarian Masses
Author(s) -
Fleischer Arthur C.,
Lyshchik Andrej,
Jones Howard W.,
Crispens Marta,
Loveless Mary,
Andreotti Rochelle F.,
Williams Phillip K.,
Fishman David A.
Publication year - 2008
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.7863/jum.2008.27.7.1011
Subject(s) - medicine , contrast enhancement , significant difference , contrast (vision) , nuclear medicine , malignant disease , radiology , magnetic resonance imaging , cancer , artificial intelligence , computer science
Objective. The aim of this prospective study was to evaluate differences in contrast enhancement and contrast enhancement kinetics in benign versus malignant ovarian masses with pulse inversion harmonic transvaginal sonography. Methods. Seventeen consecutive patients with 23 morphologically abnormal ovarian masses (solid or cystic with papillary excrescences, focally thickened walls, or irregular solid areas) smaller than 10 cm received a microbubble contrast agent intravenously while undergoing pulse inversion harmonic transvaginal sonography. The following parameters were assessed in all tumors: detectable contrast enhancement, time to peak enhancement (wash‐in), peak contrast enhancement, half wash‐out time, and area under the enhancement curve. Tumor histologic analysis was used to distinguish benign from malignant ovarian tumors. Results. Fourteen benign masses and 9 malignancies were studied. There was a statistically significant difference in the peak enhancement (mean ± SD, 23.3 ± 2.8 versus 12.3 ± 3.9 dB; P < .01), half wash‐out time (139.9 ± 43.6 versus 46.3 ± 19.7 seconds; P < .01), and area under the enhancement curve (2012.9 ± 532.9 versus 523.9 ± 318 seconds −1 ; P < .01) in malignant masses compared with benign disease. There was no statistically significant difference in the time to peak enhancement (26.1 ± 6.3 versus 24.9 ± 7.6 seconds; P = .07). Conclusions. Overall, our data showed a significant difference in the contrast enhancement kinetic parameters between benign and malignant ovarian masses.